Recent small studies suggest improved hepatocellular carcinoma (HCC)-related outcomes with transarterial radioembolization (TARE) compared with transarterial chemoembolization (TACE), although it is unclear whether this translates into superior transplant-related outcomes. We aimed to compare waitlist outcomes for TARE vs. TACE as first-line locoregional treatment (LRT) for HCC in the contemporary MMaT (median MELD at transplant minus 3) era, with standardized wait times nationwide.
Recent small studies suggest improved hepatocellular carcinoma (HCC)-related outcomes with transarterial radioembolization (TARE) compared with transarterial chemoembolization (TACE), although it is unclear whether this translates into superior transplant-related outcomes. We aimed to compare waitlist outcomes for TARE vs. TACE as first-line locoregional treatment (LRT) for HCC in the contemporary MMaT (median MELD at transplant minus 3) era, with standardized wait times nationwide.